Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway

Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway

Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of CFZ-induced cardiovascular toxicity are not fully understood but endothelial dysfunction may be a common denominator. Here,...

Full description

Bibliographic Details
Main Authors: Mohamed S. Dabour, Ibrahim Y. Abdelgawad, Marianne K.O. Grant, Engie S. El-Sawaf, Beshay N. Zordoky
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Carfilzomib
SGLT2 inhibitors
Canagliflozin
Endothelial Cells
AMPK
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223006972

Similar Items

Similar Items